Preprint Review Version 5 Preserved in Portico This version is not peer-reviewed

Convalescent Plasma Therapy for Covid-19: State of the Art

Version 1 : Received: 6 April 2020 / Approved: 7 April 2020 / Online: 7 April 2020 (11:47:15 CEST)
Version 2 : Received: 8 April 2020 / Approved: 8 April 2020 / Online: 8 April 2020 (11:43:14 CEST)
Version 3 : Received: 11 April 2020 / Approved: 13 April 2020 / Online: 13 April 2020 (10:56:12 CEST)
Version 4 : Received: 20 April 2020 / Approved: 22 April 2020 / Online: 22 April 2020 (09:50:33 CEST)
Version 5 : Received: 27 April 2020 / Approved: 28 April 2020 / Online: 28 April 2020 (09:37:10 CEST)
Version 6 : Received: 27 May 2020 / Approved: 28 May 2020 / Online: 28 May 2020 (11:52:38 CEST)
Version 7 : Received: 1 July 2020 / Approved: 1 July 2020 / Online: 1 July 2020 (14:12:21 CEST)

How to cite: Focosi, D.; Tang, J.; Anderson, A.; Tuccori, M. Convalescent Plasma Therapy for Covid-19: State of the Art. Preprints 2020, 2020040097 (doi: 10.20944/preprints202004.0097.v5). Focosi, D.; Tang, J.; Anderson, A.; Tuccori, M. Convalescent Plasma Therapy for Covid-19: State of the Art. Preprints 2020, 2020040097 (doi: 10.20944/preprints202004.0097.v5).

Abstract

Convalescent blood product therapy has been introduced since early 1900s to treat emerging infectious disease based on the evidence that polyclonal neutralizing antibodies can reduce duration of viremia. Recent large outbreaks of viral diseases for whom effective antivirals or vaccines are still lacking has revamped the interest in convalescent plasma as life-saving treatments. This review summarizes historical settings of application, and surveys current technologies for collection, manufacturing, pathogen inactivation, and banking, with a focus on COVID-19.

Subject Areas

convalescent plasma; serology; pathogen reduction technologies; pathogen inactivation; COVID-19; SARS-CoV2

Comments (1)

Comment 1
Received: 28 April 2020
Commenter: Daniele Focosi
Commenter's Conflict of Interests: Author
Comment: Updated and redesigned Table 1 according to clinical trial phase and disease stage. Updated ADE paragraph.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.